Jewellery stocks, the likes of PC Jeweller and Titan Company which were up between 3-4 percent while ICICI Bank was the top gainer in the Nifty50 Index while SPARC plunged 11 percent intraday.
Anil Raghavan, CEO, SPARC, the results confirms that device is highly efficient and consistent in delivering more drug to the lungs and suitable for all classes of patients.
Bajaj Auto | Laurus Labs | M&M | Bhushan Steel | SPARC | Deccan Cement are stocks, which are in news today.
Shares of Sun Pharma Advanced Research Company, the subsidiary of healthcare major Sun Pharmaceutical, surged nearly 7 percent intraday Thursday after receiving complete response letter from the US health regulator for preservative-free eye drop.
The selling pressure continued for the seventh consecutive session today due to lack of positive triggers. The market may be factoring in the impact of demonetisation on December quarter earnings, December sales data and economic data that will be announced next month.
Mitesh Thacker of miteshthacker.com is of the view that one may buy Tata Steel and advises selling Infosys.
Rajat Bose of rajatkbose.com feels that Cadila Healthcare may test Rs 393.
Mitesh Thacker of miteshthacker.com advises buying Sun Pharma Advanced Research Company.
Sun Pharma Advanced Research Company Q4 reported a slight increase in its standalone net loss atat Rs 9.58 crore for the quarter to March 2016
Sharmila Joshi of sharmilajoshi.com is of the view that one may hold Sun Pharma Advanced Research Company.
Sandeep Wagle of powermywealth.com is of the view that one may hold Sun Pharma Advanced Research Company with long term perspective.
Tata Steel, Vedanta, TCS, Hindalco Industries, SBI, HDFC and IndusInd Bank rallied 1.5-2.5 percent. The Indian rupee gained 9 paise in early trade today. It has opened at 65.87 per dollar against previous close of 65.96.
Levetiracetam is an antiepileptic drug (AED) indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.
The steep reduction in loss was due to break even at EBITDA level (earnings before interest, tax, depreciation and amortisation) against loss of Rs 9.5 crore in the corresponding quarter of last fiscal.
India's largest drugmaker Sun Pharma may file application for a new drug with the US Food and Drug Administration in next two to three years, the company's Managing Director Dilip Shanghvi said on Thursday.
Shares of Sun Pharmaceutical Industries slipped 1 percent intraday Tuesday after the company's active pharma ingredients plant in Ahmednagar (in Maharashtra) audited by the American drug regulator USFDA last month.
During the audit of Sun Pharma's Active Pharma Ingredients plant in Ahmednagar by US FDA, minor compliance observations were noted, which won't impact the facility adversely.
Shares of Sun Pharmaceutical Industries climbed 2 percent intraday Thursday on getting the approval from US Food and Drug Administration for Donepezil hydrochloride.
BF Utilities rallied 8 percent in addition to 14 percent upside in previous session while SPARC climbed over a percent after rising 15 percent on Monday.
Sun Pharma, HUL, HDFC twins and Cipla were top gainers in the Sensex. Hindalco, Coal India, GAIL, TCS and Sesa Sterlite are major laggards.
Shares of Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company (SPARC) rallied 9-10 percent intraday on Wednesday to hit record highs of Rs 1,035 and Rs 448.80, respectively. SPARC, the subsidiary of pharma major, has received approval from US Food and Drug Administration (USFDA) for antiepileptic drug.
Nooresh Merani of AMSEC Research recommends buying Voltas with a target of Rs 98 and PTC India with a target of Rs 64.
Income from operations of Sun Pharma Advanced Research Company rose to Rs 25.84 crore for the second quarter ended September 30, 2013.
Rajesh Agarwal of Eastern Financiers recommends buying Sun Pharma Advanced Research Company with a target of Rs 138 and Apollo Hospitals Enterprises with a target of Rs 950.
Oracle's big memory machines are ideal for in-memory applications and consolidation.